"Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug" was originally created and published by Clinical ...

On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis.

"Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has ...

In ulcerative colitis, duvakitug led to clinical remission in ... Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ...

After Phase 2 duvakitug data surpassed ... UBS believes Teva is still an under-owned name among Long-only, which UBS expects can change in 2025 as brand transition accelerates and the company ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Just 13% of those in the placebo arm met that mark. Teva said these responses to duvakitug were both statistically significant and clinically meaningful. Who accredits health plans for mental ...

This includes 16% sales growth in the U.S., totalling $1 billion, as well as 8% growth in Europe, totalling $970 million As for brand name products ... Of note, Teva said it expects results of ...